Icosavax

Acquired

Icosavax was founded in 2018, is headquartered in Seattle, United States, and has $151.0M in recorded funding across 2 rounds.

Founded
2018
Business Model
B2B
Total Funding
$151.0M
Last Round
$100.0M Series BApr 2021
Rounds
2
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 5 investors for this company. The full record is or through the API.

About

Icosavax was a clinical-stage biopharmaceutical company that developed next-generation vaccines using computationally designed virus-like particle (VLP) technology, originally spun out of the University of Washington Institute for Protein Design in 2018. The company's platform enabled the engineering of synthetic nanoparticles that closely mimic natural viruses to elicit potent immune responses, with lead programs targeting RSV and hMPV. Icosavax's VLP-based approach offered a differentiated alternative to mRNA and traditional vaccine modalities. The company was acquired by AstraZeneca in early 2024 for approximately $1.1 billion.

Summary

Icosavax is a Biotech company based in Seattle, United States, founded in 2018. It has raised $151.0M in total across 2 rounds, most recently a $100.0M Series B round in Apr 2021. Investors include Omega Funds, RA Capital Management and Viking Global.

Funding & Exit History

IPOSep 2021
$209.3M

Sign up to see all 4 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Icosavax on Indexed.vc
<a href="https://indexed.vc/companies/icosavax"><img src="https://indexed.vc/api/badge/company/icosavax" alt="Icosavax on Indexed.vc" width="260" height="76" /></a>